LISTED EURONEXT Paris NASDAQ Copenhagen

EPA ONXEO

TODAYrsquoS SCIENCE TARGETING TUMOR

DNA FUNCTIONS

TOMORROWrsquoS NEW HOPE AGAINST RESISTANT CANCER

June 2020

IMPORTANT You must read the following before continuing In accessing this document you agree to be bound by the following terms and conditions

This document has been prepared by Onxeo SA (together with its subsidiaries the Group) and is for information purposes only The content of this document is provisional and for information purposes only and is notto be construed as providing investment advice The information statements and opinions contained in this document (the ldquoInformationrdquo) are provided as of the date of this document only and June be subject tosignificant changes at any time without notice Neither the Group nor its advisors nor any other person is under any obligation to update the Information Subject to applicable law none of the Company or its advisorsaccepts any responsibility whatsoever and makes no representation or warranty express or implied as to the fairness accuracy completeness or correctness of the Information The Information has not been subject toindependent verification and is qualified in its entirety by the business financial and other information that the Group is required to publish in accordance with the rules regulations and practices applicable to companieslisted on Euronext Paris including in particular the risk factors described in in the most recent Companyrsquos Universal Registration Document filed with the French Financial Markets Authority (Autoriteacute des marcheacutesfinanciers) in any other periodic report and in any other press release which are available free of charge on the websites of the Group (wwwonxeocom) andor the AMF (wwwamf-franceorg)

This document contains information on the use of the Groups products and its competitive position Some of the Information is from third parties While this third party information has been obtained from sourcesbelieved to be reliable there is no guarantee of the accuracy or completeness of such data In addition certain of the industry and market data comes from the Groups own internal research and estimates based on theknowledge and experience of the Groups management While the Group believes that such research and estimates are reasonable and reliable they and their underlying methodology and assumptions have not beenverified by any independent source for accuracy or completeness and are subject to change without notice Accordingly undue reliance should not be placed on any of the industry market or competitive position datacontained in the Information

The Information is not directed to or intended for distribution to or use by any person or entity that is a citizen or resident of or located in any locality state country or other jurisdiction where such distribution or usewould be contrary to law or regulation or which would require any registration or licensing within such jurisdiction The Information does not constitute or form part of and should not be construed as an offer or thesolicitation of an offer to subscribe for or purchase of any securities No public offering of securities June be conducted in France prior to the delivery by the French Financial Markets Authority of a visa on a prospectusthat complies with the provisions of Directive 200371CE as amended This document is for information purposes only and does not constitute an offering document or an offer of securities to the public in the UnitedKingdom to which section 85 of the Financial Services and Markets Act 2000 of the United Kingdom applies Securities June not be offered or sold in the United States absent registration under the US Securities Act of1933 as amended or an exemption from registration thereunder

This document contains certain forward-looking statements All statements in this document other than statements of historical fact are or June be deemed to be forward looking statements These statements are notguarantees of the Groups future performance These forward-looking statements relate without limitation to the Groups future prospects developments marketing strategy regulatory calendar clinical milestonesassumptions and hypothesis clinical development approach and financial requirements and are based on analyses of earnings forecasts and estimates of amounts not yet determinable and other financial and non-financial information Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that June or June not materialize in the futureForward-looking statements cannot under any circumstance be construed as a guarantee of the Groups future performance as to strategic regulatory financial or other matters and the Grouprsquos actual performanceincluding its financial position results and cash flow as well as the trends in the sector in which the Group operates June differ materially from those proposed or reflected in the forward-looking statements contained inthis document Even if the Grouprsquos performance including its financial position results cash-flows and developments in the sector in which the Group operates were to conform to the forward-looking statementscontained in this document such results or developments cannot be construed as a reliable indication of the Groups future results or developments The Group expressly declines any obligation to update or to confirmprojections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that June occur after the date of this document

Important Information

June 2020

Developing disruptive therapies in the field of DNA Damage Response (DDR) to address unmet needs in oncology

3

NEXT KEY MILESTONES FUNDEDFinancial visibility to Q1 2022 supports strategic plan to deliver key near-term clinical milestones

STRONG MANAGEMENT amp OPERATIONAL TEAMA highly skilled team of 30 with strong translational amp clinical expertise led by experienced management and board of directors with demonstrated track record in product amp business development

DIFFERENTIATED SCIENCE IN DNA DAMAGE RESPONSEPlatONtrade proprietary chemistry platform of decoy oligonucleotides generating new compounds

AsiDNAtrade lead candidate at clinical stage a first-in-class decoy agonist showing unique anti-tumoral propertiesOX401 a newly optimized next-gen PARPi

A WELL-DEFINED BUSINESS MODELCreate value by bringing drug candidates from preclinical stage to proof-of concept in man the best inflection points to monetize these assets and generate revenues

LISTED EURONEXT Paris NASDAQ Copenhagen

EPA ONXEO

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

June 2020

FRANCOISE BONO (PHD)

CSO(Sanofi Evotec)

Formerly Executive Vice-President Oncology of Evotec

Experienced management team with demonstrated track record in product amp business development

4

JUDITH GRECIET (PHARMD)

CEO

OLIVIER DE BEAUMONT (MD)

CMO(Aventis Quintiles Stallergenes Greer)

Formerly Senior Vice President Head of Global Clinical Development Pharmacovigilance and Medical Affairs ofStallergenes Greer

PHILIPPE MAITREEVP of Onxeo US CBDO

(Aventis PPD Oscient mAbRx)

Formerly Chief Executive Officer and Co-Founder of mAbRx

NICOLAS FELLMANN

CFO(Ernst amp Young Pfizer)

Formerly Director of Treasury Tax amp Audit of Pfizer France

(Pharmacia Wyeth (Pfizer) Eisai)Formerly President of Eisai France

June 2020

Current cutting-edge RampD pipeline with unique mechanisms of action in DDR

5

Programs OPTIMIZATION PRECLINICAL PHASE I PHASE Ib PHASE II

platONtrade Proprietary Platform of Decoy Oligonucleotides

OX401Next-gen PARPi + STING pathway activation

AsiDNAtrade intratumoral

AsiDNAtrade + chemotherapySynergistic efficacy

AsiDNAtrade + PARPi Resistance abrogation

AsiDNAtrade + other targeted txResistance abrogation prevention

DRIIV -1b

DRIIV study in solid tumors

GENERATION OF NEW COMPOUNDS TARGETING DNA FUNCTIONS

DN

A D

amag

e

Re

spo

nse

Ongoing proof-of concept

Ongoing proof-of concept

DD

R

+ IO

REVocan

Completed or ongoing Legend Planned short-term

AsiDNAtrade

Unique Decoy Agonist Mechanism of Action in DNA Damage Response

June 2020

AsiDNAtrade a first-in-class product in DNA Damage Response (DDR)

7

A purpose-designed cholesterol-oligonucleotide conjugate

5rsquo

3rsquo

3rsquo

5rsquo

Double-stranded 32 bp DNA is tethered with a loop to prevent disassociation2

Active 32 bp DNA duplex

Cholesterol

Loop

1 Berthault N et al Cancer Gene Therapy (2011) 1-12 doi 101038cgt20113 2 Quanz M et al PLoS ONE 2009 4(7) doi 101371journalpone0006298

Tumoral and nuclear uptake of the DNA mediated via a covalently linked cholesterol molecule1

Binding and activating DNA-PK and PARP signaling enzymes

Phosphorothioate substitutions at the 5rsquo and 3rsquo ends to prevent degradation1

Sequence non-homologous and not immunogenic (CpG-free)

AsiDNA is not an RNAi therapy thus avoiding the toxicity issues of this class

Patent Protection (Composition of

Matter on AsiDNAtrade amp related compounds)

until 2031

Extendable to 2036 with SPC amp PTE

Combinationpatents up to 2040

IP

June 2020

AsiDNAtrade a differentiated product in the clinically-validated field of DDR

8

Source Quanz M et al Clin Cancer Res 2009 151308-1316 Quanz M et al PLoS ONE 2009 4(7) doi 101371 journalpone0006298 Jdey W et al Clin Can Res 201622DOI 101158 1078-0432CCR-16-1193

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

DDR inhibition is clinically-validated in oncology (PARPi)

Decoy-agonist mode of action avoids compensatory mechanisms blocking the induction of resistance

AsiDNAtrade acts upstream of the DDR enabling cytotoxic activity regardless of genetic context

Cytotoxic activity is restricted to cancer cells translating into an outstanding safety profile

AsiDNAtrade mimics DNA breaks in the tumor cell (decoy) binds and hyperactivates the proteins (agonist) involved in the DDR cascade (sensing signaling and repairing) hellip

hellip diverts them away from the true damage hellip hellip leading to cellular death

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

IMPORTANT You must read the following before continuing In accessing this document you agree to be bound by the following terms and conditions

This document has been prepared by Onxeo SA (together with its subsidiaries the Group) and is for information purposes only The content of this document is provisional and for information purposes only and is notto be construed as providing investment advice The information statements and opinions contained in this document (the ldquoInformationrdquo) are provided as of the date of this document only and June be subject tosignificant changes at any time without notice Neither the Group nor its advisors nor any other person is under any obligation to update the Information Subject to applicable law none of the Company or its advisorsaccepts any responsibility whatsoever and makes no representation or warranty express or implied as to the fairness accuracy completeness or correctness of the Information The Information has not been subject toindependent verification and is qualified in its entirety by the business financial and other information that the Group is required to publish in accordance with the rules regulations and practices applicable to companieslisted on Euronext Paris including in particular the risk factors described in in the most recent Companyrsquos Universal Registration Document filed with the French Financial Markets Authority (Autoriteacute des marcheacutesfinanciers) in any other periodic report and in any other press release which are available free of charge on the websites of the Group (wwwonxeocom) andor the AMF (wwwamf-franceorg)

This document contains information on the use of the Groups products and its competitive position Some of the Information is from third parties While this third party information has been obtained from sourcesbelieved to be reliable there is no guarantee of the accuracy or completeness of such data In addition certain of the industry and market data comes from the Groups own internal research and estimates based on theknowledge and experience of the Groups management While the Group believes that such research and estimates are reasonable and reliable they and their underlying methodology and assumptions have not beenverified by any independent source for accuracy or completeness and are subject to change without notice Accordingly undue reliance should not be placed on any of the industry market or competitive position datacontained in the Information

The Information is not directed to or intended for distribution to or use by any person or entity that is a citizen or resident of or located in any locality state country or other jurisdiction where such distribution or usewould be contrary to law or regulation or which would require any registration or licensing within such jurisdiction The Information does not constitute or form part of and should not be construed as an offer or thesolicitation of an offer to subscribe for or purchase of any securities No public offering of securities June be conducted in France prior to the delivery by the French Financial Markets Authority of a visa on a prospectusthat complies with the provisions of Directive 200371CE as amended This document is for information purposes only and does not constitute an offering document or an offer of securities to the public in the UnitedKingdom to which section 85 of the Financial Services and Markets Act 2000 of the United Kingdom applies Securities June not be offered or sold in the United States absent registration under the US Securities Act of1933 as amended or an exemption from registration thereunder

This document contains certain forward-looking statements All statements in this document other than statements of historical fact are or June be deemed to be forward looking statements These statements are notguarantees of the Groups future performance These forward-looking statements relate without limitation to the Groups future prospects developments marketing strategy regulatory calendar clinical milestonesassumptions and hypothesis clinical development approach and financial requirements and are based on analyses of earnings forecasts and estimates of amounts not yet determinable and other financial and non-financial information Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that June or June not materialize in the futureForward-looking statements cannot under any circumstance be construed as a guarantee of the Groups future performance as to strategic regulatory financial or other matters and the Grouprsquos actual performanceincluding its financial position results and cash flow as well as the trends in the sector in which the Group operates June differ materially from those proposed or reflected in the forward-looking statements contained inthis document Even if the Grouprsquos performance including its financial position results cash-flows and developments in the sector in which the Group operates were to conform to the forward-looking statementscontained in this document such results or developments cannot be construed as a reliable indication of the Groups future results or developments The Group expressly declines any obligation to update or to confirmprojections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that June occur after the date of this document

Important Information

June 2020

Developing disruptive therapies in the field of DNA Damage Response (DDR) to address unmet needs in oncology

3

NEXT KEY MILESTONES FUNDEDFinancial visibility to Q1 2022 supports strategic plan to deliver key near-term clinical milestones

STRONG MANAGEMENT amp OPERATIONAL TEAMA highly skilled team of 30 with strong translational amp clinical expertise led by experienced management and board of directors with demonstrated track record in product amp business development

DIFFERENTIATED SCIENCE IN DNA DAMAGE RESPONSEPlatONtrade proprietary chemistry platform of decoy oligonucleotides generating new compounds

AsiDNAtrade lead candidate at clinical stage a first-in-class decoy agonist showing unique anti-tumoral propertiesOX401 a newly optimized next-gen PARPi

A WELL-DEFINED BUSINESS MODELCreate value by bringing drug candidates from preclinical stage to proof-of concept in man the best inflection points to monetize these assets and generate revenues

LISTED EURONEXT Paris NASDAQ Copenhagen

EPA ONXEO

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

June 2020

FRANCOISE BONO (PHD)

CSO(Sanofi Evotec)

Formerly Executive Vice-President Oncology of Evotec

Experienced management team with demonstrated track record in product amp business development

4

JUDITH GRECIET (PHARMD)

CEO

OLIVIER DE BEAUMONT (MD)

CMO(Aventis Quintiles Stallergenes Greer)

Formerly Senior Vice President Head of Global Clinical Development Pharmacovigilance and Medical Affairs ofStallergenes Greer

PHILIPPE MAITREEVP of Onxeo US CBDO

(Aventis PPD Oscient mAbRx)

Formerly Chief Executive Officer and Co-Founder of mAbRx

NICOLAS FELLMANN

CFO(Ernst amp Young Pfizer)

Formerly Director of Treasury Tax amp Audit of Pfizer France

(Pharmacia Wyeth (Pfizer) Eisai)Formerly President of Eisai France

June 2020

Current cutting-edge RampD pipeline with unique mechanisms of action in DDR

5

Programs OPTIMIZATION PRECLINICAL PHASE I PHASE Ib PHASE II

platONtrade Proprietary Platform of Decoy Oligonucleotides

OX401Next-gen PARPi + STING pathway activation

AsiDNAtrade intratumoral

AsiDNAtrade + chemotherapySynergistic efficacy

AsiDNAtrade + PARPi Resistance abrogation

AsiDNAtrade + other targeted txResistance abrogation prevention

DRIIV -1b

DRIIV study in solid tumors

GENERATION OF NEW COMPOUNDS TARGETING DNA FUNCTIONS

DN

A D

amag

e

Re

spo

nse

Ongoing proof-of concept

Ongoing proof-of concept

DD

R

+ IO

REVocan

Completed or ongoing Legend Planned short-term

AsiDNAtrade

Unique Decoy Agonist Mechanism of Action in DNA Damage Response

June 2020

AsiDNAtrade a first-in-class product in DNA Damage Response (DDR)

7

A purpose-designed cholesterol-oligonucleotide conjugate

5rsquo

3rsquo

3rsquo

5rsquo

Double-stranded 32 bp DNA is tethered with a loop to prevent disassociation2

Active 32 bp DNA duplex

Cholesterol

Loop

1 Berthault N et al Cancer Gene Therapy (2011) 1-12 doi 101038cgt20113 2 Quanz M et al PLoS ONE 2009 4(7) doi 101371journalpone0006298

Tumoral and nuclear uptake of the DNA mediated via a covalently linked cholesterol molecule1

Binding and activating DNA-PK and PARP signaling enzymes

Phosphorothioate substitutions at the 5rsquo and 3rsquo ends to prevent degradation1

Sequence non-homologous and not immunogenic (CpG-free)

AsiDNA is not an RNAi therapy thus avoiding the toxicity issues of this class

Patent Protection (Composition of

Matter on AsiDNAtrade amp related compounds)

until 2031

Extendable to 2036 with SPC amp PTE

Combinationpatents up to 2040

IP

June 2020

AsiDNAtrade a differentiated product in the clinically-validated field of DDR

8

Source Quanz M et al Clin Cancer Res 2009 151308-1316 Quanz M et al PLoS ONE 2009 4(7) doi 101371 journalpone0006298 Jdey W et al Clin Can Res 201622DOI 101158 1078-0432CCR-16-1193

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

DDR inhibition is clinically-validated in oncology (PARPi)

Decoy-agonist mode of action avoids compensatory mechanisms blocking the induction of resistance

AsiDNAtrade acts upstream of the DDR enabling cytotoxic activity regardless of genetic context

Cytotoxic activity is restricted to cancer cells translating into an outstanding safety profile

AsiDNAtrade mimics DNA breaks in the tumor cell (decoy) binds and hyperactivates the proteins (agonist) involved in the DDR cascade (sensing signaling and repairing) hellip

hellip diverts them away from the true damage hellip hellip leading to cellular death

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Developing disruptive therapies in the field of DNA Damage Response (DDR) to address unmet needs in oncology

3

NEXT KEY MILESTONES FUNDEDFinancial visibility to Q1 2022 supports strategic plan to deliver key near-term clinical milestones

STRONG MANAGEMENT amp OPERATIONAL TEAMA highly skilled team of 30 with strong translational amp clinical expertise led by experienced management and board of directors with demonstrated track record in product amp business development

DIFFERENTIATED SCIENCE IN DNA DAMAGE RESPONSEPlatONtrade proprietary chemistry platform of decoy oligonucleotides generating new compounds

AsiDNAtrade lead candidate at clinical stage a first-in-class decoy agonist showing unique anti-tumoral propertiesOX401 a newly optimized next-gen PARPi

A WELL-DEFINED BUSINESS MODELCreate value by bringing drug candidates from preclinical stage to proof-of concept in man the best inflection points to monetize these assets and generate revenues

LISTED EURONEXT Paris NASDAQ Copenhagen

EPA ONXEO

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

June 2020

FRANCOISE BONO (PHD)

CSO(Sanofi Evotec)

Formerly Executive Vice-President Oncology of Evotec

Experienced management team with demonstrated track record in product amp business development

4

JUDITH GRECIET (PHARMD)

CEO

OLIVIER DE BEAUMONT (MD)

CMO(Aventis Quintiles Stallergenes Greer)

Formerly Senior Vice President Head of Global Clinical Development Pharmacovigilance and Medical Affairs ofStallergenes Greer

PHILIPPE MAITREEVP of Onxeo US CBDO

(Aventis PPD Oscient mAbRx)

Formerly Chief Executive Officer and Co-Founder of mAbRx

NICOLAS FELLMANN

CFO(Ernst amp Young Pfizer)

Formerly Director of Treasury Tax amp Audit of Pfizer France

(Pharmacia Wyeth (Pfizer) Eisai)Formerly President of Eisai France

June 2020

Current cutting-edge RampD pipeline with unique mechanisms of action in DDR

5

Programs OPTIMIZATION PRECLINICAL PHASE I PHASE Ib PHASE II

platONtrade Proprietary Platform of Decoy Oligonucleotides

OX401Next-gen PARPi + STING pathway activation

AsiDNAtrade intratumoral

AsiDNAtrade + chemotherapySynergistic efficacy

AsiDNAtrade + PARPi Resistance abrogation

AsiDNAtrade + other targeted txResistance abrogation prevention

DRIIV -1b

DRIIV study in solid tumors

GENERATION OF NEW COMPOUNDS TARGETING DNA FUNCTIONS

DN

A D

amag

e

Re

spo

nse

Ongoing proof-of concept

Ongoing proof-of concept

DD

R

+ IO

REVocan

Completed or ongoing Legend Planned short-term

AsiDNAtrade

Unique Decoy Agonist Mechanism of Action in DNA Damage Response

June 2020

AsiDNAtrade a first-in-class product in DNA Damage Response (DDR)

7

A purpose-designed cholesterol-oligonucleotide conjugate

5rsquo

3rsquo

3rsquo

5rsquo

Double-stranded 32 bp DNA is tethered with a loop to prevent disassociation2

Active 32 bp DNA duplex

Cholesterol

Loop

1 Berthault N et al Cancer Gene Therapy (2011) 1-12 doi 101038cgt20113 2 Quanz M et al PLoS ONE 2009 4(7) doi 101371journalpone0006298

Tumoral and nuclear uptake of the DNA mediated via a covalently linked cholesterol molecule1

Binding and activating DNA-PK and PARP signaling enzymes

Phosphorothioate substitutions at the 5rsquo and 3rsquo ends to prevent degradation1

Sequence non-homologous and not immunogenic (CpG-free)

AsiDNA is not an RNAi therapy thus avoiding the toxicity issues of this class

Patent Protection (Composition of

Matter on AsiDNAtrade amp related compounds)

until 2031

Extendable to 2036 with SPC amp PTE

Combinationpatents up to 2040

IP

June 2020

AsiDNAtrade a differentiated product in the clinically-validated field of DDR

8

Source Quanz M et al Clin Cancer Res 2009 151308-1316 Quanz M et al PLoS ONE 2009 4(7) doi 101371 journalpone0006298 Jdey W et al Clin Can Res 201622DOI 101158 1078-0432CCR-16-1193

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

DDR inhibition is clinically-validated in oncology (PARPi)

Decoy-agonist mode of action avoids compensatory mechanisms blocking the induction of resistance

AsiDNAtrade acts upstream of the DDR enabling cytotoxic activity regardless of genetic context

Cytotoxic activity is restricted to cancer cells translating into an outstanding safety profile

AsiDNAtrade mimics DNA breaks in the tumor cell (decoy) binds and hyperactivates the proteins (agonist) involved in the DDR cascade (sensing signaling and repairing) hellip

hellip diverts them away from the true damage hellip hellip leading to cellular death

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

FRANCOISE BONO (PHD)

CSO(Sanofi Evotec)

Formerly Executive Vice-President Oncology of Evotec

Experienced management team with demonstrated track record in product amp business development

4

JUDITH GRECIET (PHARMD)

CEO

OLIVIER DE BEAUMONT (MD)

CMO(Aventis Quintiles Stallergenes Greer)

Formerly Senior Vice President Head of Global Clinical Development Pharmacovigilance and Medical Affairs ofStallergenes Greer

PHILIPPE MAITREEVP of Onxeo US CBDO

(Aventis PPD Oscient mAbRx)

Formerly Chief Executive Officer and Co-Founder of mAbRx

NICOLAS FELLMANN

CFO(Ernst amp Young Pfizer)

Formerly Director of Treasury Tax amp Audit of Pfizer France

(Pharmacia Wyeth (Pfizer) Eisai)Formerly President of Eisai France

June 2020

Current cutting-edge RampD pipeline with unique mechanisms of action in DDR

5

Programs OPTIMIZATION PRECLINICAL PHASE I PHASE Ib PHASE II

platONtrade Proprietary Platform of Decoy Oligonucleotides

OX401Next-gen PARPi + STING pathway activation

AsiDNAtrade intratumoral

AsiDNAtrade + chemotherapySynergistic efficacy

AsiDNAtrade + PARPi Resistance abrogation

AsiDNAtrade + other targeted txResistance abrogation prevention

DRIIV -1b

DRIIV study in solid tumors

GENERATION OF NEW COMPOUNDS TARGETING DNA FUNCTIONS

DN

A D

amag

e

Re

spo

nse

Ongoing proof-of concept

Ongoing proof-of concept

DD

R

+ IO

REVocan

Completed or ongoing Legend Planned short-term

AsiDNAtrade

Unique Decoy Agonist Mechanism of Action in DNA Damage Response

June 2020

AsiDNAtrade a first-in-class product in DNA Damage Response (DDR)

7

A purpose-designed cholesterol-oligonucleotide conjugate

5rsquo

3rsquo

3rsquo

5rsquo

Double-stranded 32 bp DNA is tethered with a loop to prevent disassociation2

Active 32 bp DNA duplex

Cholesterol

Loop

1 Berthault N et al Cancer Gene Therapy (2011) 1-12 doi 101038cgt20113 2 Quanz M et al PLoS ONE 2009 4(7) doi 101371journalpone0006298

Tumoral and nuclear uptake of the DNA mediated via a covalently linked cholesterol molecule1

Binding and activating DNA-PK and PARP signaling enzymes

Phosphorothioate substitutions at the 5rsquo and 3rsquo ends to prevent degradation1

Sequence non-homologous and not immunogenic (CpG-free)

AsiDNA is not an RNAi therapy thus avoiding the toxicity issues of this class

Patent Protection (Composition of

Matter on AsiDNAtrade amp related compounds)

until 2031

Extendable to 2036 with SPC amp PTE

Combinationpatents up to 2040

IP

June 2020

AsiDNAtrade a differentiated product in the clinically-validated field of DDR

8

Source Quanz M et al Clin Cancer Res 2009 151308-1316 Quanz M et al PLoS ONE 2009 4(7) doi 101371 journalpone0006298 Jdey W et al Clin Can Res 201622DOI 101158 1078-0432CCR-16-1193

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

DDR inhibition is clinically-validated in oncology (PARPi)

Decoy-agonist mode of action avoids compensatory mechanisms blocking the induction of resistance

AsiDNAtrade acts upstream of the DDR enabling cytotoxic activity regardless of genetic context

Cytotoxic activity is restricted to cancer cells translating into an outstanding safety profile

AsiDNAtrade mimics DNA breaks in the tumor cell (decoy) binds and hyperactivates the proteins (agonist) involved in the DDR cascade (sensing signaling and repairing) hellip

hellip diverts them away from the true damage hellip hellip leading to cellular death

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Current cutting-edge RampD pipeline with unique mechanisms of action in DDR

5

Programs OPTIMIZATION PRECLINICAL PHASE I PHASE Ib PHASE II

platONtrade Proprietary Platform of Decoy Oligonucleotides

OX401Next-gen PARPi + STING pathway activation

AsiDNAtrade intratumoral

AsiDNAtrade + chemotherapySynergistic efficacy

AsiDNAtrade + PARPi Resistance abrogation

AsiDNAtrade + other targeted txResistance abrogation prevention

DRIIV -1b

DRIIV study in solid tumors

GENERATION OF NEW COMPOUNDS TARGETING DNA FUNCTIONS

DN

A D

amag

e

Re

spo

nse

Ongoing proof-of concept

Ongoing proof-of concept

DD

R

+ IO

REVocan

Completed or ongoing Legend Planned short-term

AsiDNAtrade

Unique Decoy Agonist Mechanism of Action in DNA Damage Response

June 2020

AsiDNAtrade a first-in-class product in DNA Damage Response (DDR)

7

A purpose-designed cholesterol-oligonucleotide conjugate

5rsquo

3rsquo

3rsquo

5rsquo

Double-stranded 32 bp DNA is tethered with a loop to prevent disassociation2

Active 32 bp DNA duplex

Cholesterol

Loop

1 Berthault N et al Cancer Gene Therapy (2011) 1-12 doi 101038cgt20113 2 Quanz M et al PLoS ONE 2009 4(7) doi 101371journalpone0006298

Tumoral and nuclear uptake of the DNA mediated via a covalently linked cholesterol molecule1

Binding and activating DNA-PK and PARP signaling enzymes

Phosphorothioate substitutions at the 5rsquo and 3rsquo ends to prevent degradation1

Sequence non-homologous and not immunogenic (CpG-free)

AsiDNA is not an RNAi therapy thus avoiding the toxicity issues of this class

Patent Protection (Composition of

Matter on AsiDNAtrade amp related compounds)

until 2031

Extendable to 2036 with SPC amp PTE

Combinationpatents up to 2040

IP

June 2020

AsiDNAtrade a differentiated product in the clinically-validated field of DDR

8

Source Quanz M et al Clin Cancer Res 2009 151308-1316 Quanz M et al PLoS ONE 2009 4(7) doi 101371 journalpone0006298 Jdey W et al Clin Can Res 201622DOI 101158 1078-0432CCR-16-1193

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

DDR inhibition is clinically-validated in oncology (PARPi)

Decoy-agonist mode of action avoids compensatory mechanisms blocking the induction of resistance

AsiDNAtrade acts upstream of the DDR enabling cytotoxic activity regardless of genetic context

Cytotoxic activity is restricted to cancer cells translating into an outstanding safety profile

AsiDNAtrade mimics DNA breaks in the tumor cell (decoy) binds and hyperactivates the proteins (agonist) involved in the DDR cascade (sensing signaling and repairing) hellip

hellip diverts them away from the true damage hellip hellip leading to cellular death

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

AsiDNAtrade

Unique Decoy Agonist Mechanism of Action in DNA Damage Response

June 2020

AsiDNAtrade a first-in-class product in DNA Damage Response (DDR)

7

A purpose-designed cholesterol-oligonucleotide conjugate

5rsquo

3rsquo

3rsquo

5rsquo

Double-stranded 32 bp DNA is tethered with a loop to prevent disassociation2

Active 32 bp DNA duplex

Cholesterol

Loop

1 Berthault N et al Cancer Gene Therapy (2011) 1-12 doi 101038cgt20113 2 Quanz M et al PLoS ONE 2009 4(7) doi 101371journalpone0006298

Tumoral and nuclear uptake of the DNA mediated via a covalently linked cholesterol molecule1

Binding and activating DNA-PK and PARP signaling enzymes

Phosphorothioate substitutions at the 5rsquo and 3rsquo ends to prevent degradation1

Sequence non-homologous and not immunogenic (CpG-free)

AsiDNA is not an RNAi therapy thus avoiding the toxicity issues of this class

Patent Protection (Composition of

Matter on AsiDNAtrade amp related compounds)

until 2031

Extendable to 2036 with SPC amp PTE

Combinationpatents up to 2040

IP

June 2020

AsiDNAtrade a differentiated product in the clinically-validated field of DDR

8

Source Quanz M et al Clin Cancer Res 2009 151308-1316 Quanz M et al PLoS ONE 2009 4(7) doi 101371 journalpone0006298 Jdey W et al Clin Can Res 201622DOI 101158 1078-0432CCR-16-1193

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

DDR inhibition is clinically-validated in oncology (PARPi)

Decoy-agonist mode of action avoids compensatory mechanisms blocking the induction of resistance

AsiDNAtrade acts upstream of the DDR enabling cytotoxic activity regardless of genetic context

Cytotoxic activity is restricted to cancer cells translating into an outstanding safety profile

AsiDNAtrade mimics DNA breaks in the tumor cell (decoy) binds and hyperactivates the proteins (agonist) involved in the DDR cascade (sensing signaling and repairing) hellip

hellip diverts them away from the true damage hellip hellip leading to cellular death

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

AsiDNAtrade a first-in-class product in DNA Damage Response (DDR)

7

A purpose-designed cholesterol-oligonucleotide conjugate

5rsquo

3rsquo

3rsquo

5rsquo

Double-stranded 32 bp DNA is tethered with a loop to prevent disassociation2

Active 32 bp DNA duplex

Cholesterol

Loop

1 Berthault N et al Cancer Gene Therapy (2011) 1-12 doi 101038cgt20113 2 Quanz M et al PLoS ONE 2009 4(7) doi 101371journalpone0006298

Tumoral and nuclear uptake of the DNA mediated via a covalently linked cholesterol molecule1

Binding and activating DNA-PK and PARP signaling enzymes

Phosphorothioate substitutions at the 5rsquo and 3rsquo ends to prevent degradation1

Sequence non-homologous and not immunogenic (CpG-free)

AsiDNA is not an RNAi therapy thus avoiding the toxicity issues of this class

Patent Protection (Composition of

Matter on AsiDNAtrade amp related compounds)

until 2031

Extendable to 2036 with SPC amp PTE

Combinationpatents up to 2040

IP

June 2020

AsiDNAtrade a differentiated product in the clinically-validated field of DDR

8

Source Quanz M et al Clin Cancer Res 2009 151308-1316 Quanz M et al PLoS ONE 2009 4(7) doi 101371 journalpone0006298 Jdey W et al Clin Can Res 201622DOI 101158 1078-0432CCR-16-1193

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

DDR inhibition is clinically-validated in oncology (PARPi)

Decoy-agonist mode of action avoids compensatory mechanisms blocking the induction of resistance

AsiDNAtrade acts upstream of the DDR enabling cytotoxic activity regardless of genetic context

Cytotoxic activity is restricted to cancer cells translating into an outstanding safety profile

AsiDNAtrade mimics DNA breaks in the tumor cell (decoy) binds and hyperactivates the proteins (agonist) involved in the DDR cascade (sensing signaling and repairing) hellip

hellip diverts them away from the true damage hellip hellip leading to cellular death

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

AsiDNAtrade a differentiated product in the clinically-validated field of DDR

8

Source Quanz M et al Clin Cancer Res 2009 151308-1316 Quanz M et al PLoS ONE 2009 4(7) doi 101371 journalpone0006298 Jdey W et al Clin Can Res 201622DOI 101158 1078-0432CCR-16-1193

PARP inhibitors (PARPi) are a leading class of targeted therapies the first approved and marketed in the field of DDR

DDR inhibition is clinically-validated in oncology (PARPi)

Decoy-agonist mode of action avoids compensatory mechanisms blocking the induction of resistance

AsiDNAtrade acts upstream of the DDR enabling cytotoxic activity regardless of genetic context

Cytotoxic activity is restricted to cancer cells translating into an outstanding safety profile

AsiDNAtrade mimics DNA breaks in the tumor cell (decoy) binds and hyperactivates the proteins (agonist) involved in the DDR cascade (sensing signaling and repairing) hellip

hellip diverts them away from the true damage hellip hellip leading to cellular death

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

AsiDNAtrade is a first-in-class therapy for combination designed to address the 1 challenge in oncology resistance to treatment

9

Decoy Agonist MoA does not induce resistance

Differentiated Decoy Agonist MoAin the clinically-validated field of DNA Damage Response

Long IP (up to 2040)

Clinical-stage assetFavorable safety profile incl in combination Proof of mechanism signals of efficacy

Strategic focus on the abrogation of resistance to targeted therapies

Collaborations with top-academic centers(Institut Curie - Gustave Roussy ndash Oncopole Toulousehellip)

REVocan Phase 1b2 to evaluate the addition of AsiDNAtrade on the abrogation resistance to niraparib (to start Q3 2020)

Depletes the cells from which resistance to targeted therapies emerge

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

An extensive preclinical program paves the way to ambitious clinical translation

10

Safety profile No cytotoxic activity in healthy cells Very favorable data in tox study (monkey)

Autosensitization and noresistance observed In multiple cell lines Confirmed

Efficacy synergy with PARPi In multiple PARPi sensitive amp resistant cell lines

No restriction to specific genetic context

AsiDNAtrade increases survival amp responders to PARPi

Efficacy synergy with chemo In multiple cell lines AsiDNAtrade increases efficacy amp survival

Abrogation of resistance to PARPi In multiple cell lines AsiDNAtrade stops resistance to PARPi

Abrogation prevention of resistance to other targeted tx

Ongoing validation with several TKI KRASi hellipPrelim data confirming prolongation of anti-EGFR anti-ALK efficacy

In vitro data In vivo data

PARP inhibitors (PARPi) and tyrosine kinase inhibitors (TKI) are leading approved targeted therapies in oncology

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

0 20 40 600

2times104

4times104

6times104

8times104

1times105

1times1062times1063times1064times1065times1066times106

Nira

Nira+Asi continuous

Nira+Asi at D34

Days post treatment

Cell

num

ber

11

UWB1289 (Ovarian Cancer model ndash BRCA1--)

AsiDNAtrade abrogates acquired resistance to PARP inhibitors (class effect)

AsiDNAtrade leads to niraparib-resistant cells eradication in ovarian cancer model even if introduced only once resistance emerges (CA 125 increase)

REVocan study (REVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib) was designed on the basis of these results

D17

D24

D31

D40

D17

D24

D31

D40

0

5

10

15

20

30

60

90

120

150

CA

12

5

(pgm

l)

Introduction at CA125 increase (REVocan study protocol)

Start of AsiDNAtrade administration

Source Onxeo data on file

niraparib

Emergence of Resistant cells

Cell death

Start of AsiDNAtrade administration

(D34)

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Results confirmed in in vivo experiments in a triple negative breast cancer model

AsiDNAtrade abrogates acquired resistance to PARP inhibitors

12

MDAMB-436 (TNBC HR deficient - PARPi sensitive)

Source Onxeo data on file

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Non Small Cell Lung Cancer model ndash anti-EGFR sensitive

AsiDNAtrade eradicates cells resistant to anti-EGFR and anti-ALK

AsiDNAtrade prevents resistance to other targeted tx such as TKI

13

0 3 5 6 7 10 12 13 14 17 21 24 27 34 38 41 46 49 52

-20

0

20

40

60

80

100

120

ErlotinibErlotinib+AsiDNA

Time (days)

Su

rviv

ing

ce

lls (

)

No surviving cells

Emergence of resistant cells

No surviving cells

Emergence of resistant cells

PC9-3 (NSCLC EGFRmut) - EGFR T790 mutation is preexisting in PC9 parental cell line PC9-3 cell line is a sub-clone of PC9 without preexisting T790M

Non Small Cell Lung Cancer model ndash anti-ALK sensitive

H3122 (NSCLC EML4-ALK)

Source Onxeo data on file

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

AsiDNAtrade

Clinical Development Plan

Validation of the Effect of AsiDNAtrade onResistance to Targeted Therapies

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Delivering the promises of AsiDNAtrade to patients

DRIIV-1 Phase 1First IV administration in solid tumors

Favorable safety via IV

Proof of mechanism in tumors

DRIIV-1b Phase 1b (IV)Combo with carboplatin +- paclitaxel (ongoing)

Excellent safety in combination with chemotherapy

Prelim signals of efficacyCohort 2 (Carboplatin + Paclitaxel) ongoing

REVOCAN Phase 1b2 (IV)Ovarian cancer in combination w PARPi niraparib

Proof of Concept Abrogation of resistance to PARPiFPI expected Q3 2020

Phase 1b2 (IV)Non small cell lung cancer in combination w other targeted therapies (TKI KRAShellip)

Proof of Concept PreventionAbrogation of resistance to targeted therapies

SHO

RT

MID

-TE

RM

ON

GO

ING

15

CO

MP

LETE

D

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

DRIIV-1 Phase 1 Favorable safety profile

Phase I study in IV

Open-label 3+3 dose escalation from 200mg to 1800mg

22 patients 5 doses

Study coordinator Pr C Le Tourneau (Institut Curie)

Objectives to determine the safety and PKPD profile of AsiDNAtrade

Primary objective reached favorable safety outcome

90 of adverse events were grade 1 2 mostly ( 77) non-related no specific type of toxicity

AsiDNAtrade 200mg 400mg 600mg No drug-related Serious Adverse Events (SAEs) and no Dose-Limiting Toxicity (DLT)

AsiDNAtrade 900mg amp 1300mg 3 related SAEs including 2 DLTs per dose

Orthostatic hypotension (grade 3 unlikely related)

2 increase of hepatic enzymes ( grade 3 unlikely related and grade 4possibly related)

Maximum Tolerated Dose (MTD) was not reached

DRIIV-1 results were presented at EORTC-NCI-AACR on 102719 16

181 (89)

22(11)

1

Grade 12 Grade 3

Non-related95

Non-related77

Adverse Events

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

DRIIV-1 Phase 1 Beyond safety proof-of-mechanism demonstrated

17

Activity pharmacodynamic biomarkers (on tumor biopsies)

AsiDNAtrade 600mg

Pre-treatment Post-treatment

γH2AX Readout of DNA-PK target engagement

Patient 003-001

Strong activation of γH2AX at cell level reflecting DNA-PK pathway engagement

γγ

DRIIV-1 study presented at EORTC-NCI-AACR 27th Oct 2019

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

DRIIV-1b Phase 1b Preliminary data confirm safety and efficacy signals

18

AsiDNAtrade 600 mg

Cohort 1

carboplatin

AsiDNAtrade 600 mg

carboplatin + paclitaxel

Cohort 26 pts

ongoing

+

+

Patients with ge 3 prior lines of treatment progressing at inclusion

Very good tolerance of the combination (no DLT)

Disease stabilized (SD) in 23 patients for 55 mo (TNBC 6th L) and 10 mo (NSCLC 3rd L)

Disease controlled with AsiDNAtrade for significantly longer than with any of the prior treatment lines

3 pts

Topline results expected end 2020

Timelines include Covid-19 impact to date and may be further reviewed

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Phase IbII study Proof-of-concept of the abrogation of resistance to PARP inhibitors by AsiDNAtrade

19

Patients selection patients under 2nd line of maintenance with niraparib gt 6 months

Inclusion at CA 125 increase (CA 125 well established predictive biomarker of resistance in OC)

n= up to 26 patients platinum-sensitive relapsed ovarian cancer

Primary objective Safety run amp CA125 decrease (GCIG criteria)

Secondary objective Efficacy PFS (RECIST criteria) - OS

REVocanREVersion of resistance in Ovarian Cancer with AsiDNAtrade and Niraparib

Study approved by regulatory authorities late May 2020FPI expected from H2 2020 =gt Preliminary data by end 2020early 2021

PI Dr Patricia Pautier (Arcagy Gineco Network)

Clinical collaboration

N = up to 26 pts amp 6 centers

Timelines include Covid-19 impact to date and may be further reviewed

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

AsiDNAtrade

Objectives amp Upcoming Milestones

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Our strategic priority validate the potential of AsiDNAtrade in combination in various types of key indications

21

Preventing resistance ndash a major challenge for targeted therapies such as PARPis amp TKIs - would lead to prolonged efficacy

❶

❷

ldquoResistance is the biggest challenge in cancer biologyrdquo (Paul Workman ndash ICR)

Strategic objectives Targeted Indications OpportunityApproval

Full Market Size

Optimal market access (fast favorable PampR)

2L with niraparib (PARPi) in ovarian cancer

Short endpoint PFSExpansion of maintenance treatment and delay new course of platinum

202526$67B (1)

Access large WW markets

Eg 1L with TKI or other targeted tx in non-smallcell lung cancer

Target specific population with high risk of progression

eg$169B (1)

for 1L NSCLC

REVocanCombo w PARPi

Combo w other targeted therapies

PampR pricing amp reimbursement - (1) GlobalData (8MM)

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Short-term key clinical catalysts in 2020early 21 with moderate impact of Covid-19 on milestones to date

22

DRIIV-1b cohort 2

Topline data

H2 2019 H1 2020 H2 2020

DRIIV-1bcohort 1

prelim data

REVOCAN First data set

DRIIV-1b cohort 2

Preliminary data

AsiDNAtrade +Txdata to support

clinical plan

AsiDNAtrade +TxData to support clinical plan

Preclinical validation of

OX401 profile

Tolerance in combination + first signals of efficacyDRIIVndash1bAsiDNAtrade +

carboplatin +-paclitaxel

REVOCANphase 1b2

AsiDNAtrade + niraparib

Clinical Research

agreement

Reversion of Resistance

Prevention of resistanceAsiDNAtrade + TKIKRAShellip

Preclinical proof-of-concept

Next-gen PARPi + activation of immune responseOX401Preclinical proof of

mechanism

Timelines include Covid-19 impact to date and may be further reviewed

FPI Reg approvals

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

Financials amp Outlook

23

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

Financial resources in line with key development milestones objectives

24

Financiegravere de la Montagne

13

Invus11

Free float76

Cash position of euro73m at 03312020

+ euro6m from transaction with Acrotech on 04062020

+ euro73m from private placement on 06092020 to Invus new long-term

shareholder amp Financiegravere de la Montagne historical shareholder

Cash runway to Q1 2022

Shares outstanding 783m

Average Daily Volume 555980 shares

Dual listing Euronext Paris amp Nasdaq Copenhagen

ISIN FR0010095596

At 06112020YTD at 06122020

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

AsiDNAtrade a promising opportunity with a unique MoA overcoming resistance

25

A promising opportunity available for licensing

Significantly de-risked pipeline assetPotential to play a cornerstone role in an oncology portfolio through multiple combinationsSizeable market potential through indications with large unmet needs

Broad development and commercial potential in multiple indications with high unmet needsFinancial visibility to Q1 2022 well beyond key clinical catalysts for the Company

Product at clinical stage with confirmed activity in man and favorable safety profile including in combination Phase 1b2 key readouts expected early 2021 to validate potential in combos and ability to abrogate resistance to targeted therapies

First-in-class DDR inhibitor the only decoy agonist in clinical development in this field Solid preclinical package supporting a broad range of potential indications

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

PublicationsBack-up slides

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

AsiDNAtrade Publications (12)

27

Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response Quanz M et al PLoS One 2009 4e6298

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers Redon CE et al Clin Cancer Res 2010 16(18)

Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems Berthault N et al Cancer Gene Ther 2011 18695-706

Heat shock protein 90 (Hsp90) is phosphorylated in response to DNA damage and accumulates in repair foci Quanz M et al J Biol Chem 2012 2878803-15

Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer Devun F et al J Gastroenterol 2012 47266-75

Pharmacokinetics and toxicity in rats and monkeys of coDbait a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol Schlegel A et al Mol Ther Nucleic Acids 2012 1e33

Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of 5 glioblastoma Coquery N et al PLoS One 20127(7)e40567

Resistance to PARP-Inhibitors in Cancer Therapy Montoni A et al Front Pharmacol 2013 4 18

Kinesin KIFC1 actively transports bare double-stranded DNA Farina F et al Nucleic Acids Res 2013 414926-37

Inhibition of DNA damage repair by artificial activation of PARP with siDNA Croset A et al Nucleic Acids Res 2013 417344-55

DNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulation Kotula E et al PLoS One 2013 8(11)e80313

Colorectal cancer metastasis the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation Devun F et al Radiology 2014 270736-46

A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma Biau J et al Neoplasia 2014 16835-44

An update on PARP inhibitors for the treatment of cancer Benefif S et al

Dbait An innovative concept to inhibit DNA repair and treat cancer Biau J et al Bull Cancer 2016 103 227ndash235

The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis Herath NI et al Mol Cancer Ther 2016 Jan15(1)15-22

Targeting DNA Repair in Cancer Beyond PARP Inhibitors Brown JS et al Cancer Discov December 21 2016 DOI 1011582159-8290CD-16-0860

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy Viallard C et al Oncotarget 2016 Mar 157(11) 12927-36

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients in with skin metastases from melanoma Le Tourneau C et al Br J Cancer 2016 June24114(11)1199-205

Potentiation of Doxurubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models Herath NI et al Eur Radiol 2017 Oct 27(10)4435-4444

Drug Driven Synthetic Lethality bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors Jdey W et al Clin Cancer Res 2017 Feb 1523(4)1001-1011

Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA Jdey W et al Cancer Res 2017 Aug 1577(16)4207-4216

June 2020

AsiDNAtrade Publications (22)

28

The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood Thierry S et al Mol Cancer Ther 2017 Dec16(12)2817ndash27

Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma Efficacy and Protein Biomarkers of Resistance in Preclinical Models Biau J et al Front Oncol 2019 Jun 199549

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy Gourley C et al J Clin Oncol 2019 June 3

AsiDNAtrade treatment induces cumulative antitumor efficacy with a low probability of acquired resistance Jdey W et al Neoplasia (2019)21 863ndash871

Preclinical studies comparing efficacy and toxicity of DNA repair inhibitors olaparib and AsiDNA in treatment of carboplatin resistant tumors Jdey W et al Front Oncol 12 November 2019 | httpsdoiorg103389fonc201901097

Posters AACR 2013

Preclinical study of Dbait an inhibitor of three DNA repair pathways in breast cancer treatment

ASCO 2015

First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma

AACR 2017

AsiDNAtrade induces tumor sensitivity to PARP inhibitors in homologous recombination proficient breast cancer

AACR 2018

AsiDNAtrade and HDAC inhibitors A cross-potentiation team work to kill tumor cellsEvolution of tumor cells under Dbait (AsiDNA) treatment results in ldquoautosensitizationrdquo

AACR 2019

AsiDNAtrade abrogates acquired resistance to PARP inhibitorsDevelopment of a Biomarker-driven patient selection strategy for AsiDNAtrade treatment

Molecular analysis of the mechanism of action of AsiDNAtrade brings new clues on DNA damage response regulationAsiDNAtrade a novel DNA repair inhibitor to radio-sensitize aggressive medulloblastomasubtypes

EORTC-NCI-AACR 2019

Phase I dose escalation study evaluating the safety pharmacokinetics (PK) and pharmacodynamics (PD) of AsiDNAtrade a first-in-class DNA Repair Inhibitor administered intravenously (IV) in patients with advanced solid tumors

AACR 2020 Virtual Meeting (Poster and audio online June 22-24 2020)

Acquired resistance to PARP inhibitors evolves from drug-tolerant persister cells vulnerable to AsiDNAtrade

CONTACTSJudith Greciet ndash CEO

Nicolas Fellmann ndash CFOFranccediloise Bono ndash CSO

Olivier de Beaumont ndash CMO

Tel +33 1 45 58 76 00COMPANY INFORMATION

wwwonxeocominvestorsonxeocom